earnings
confidence high
sentiment positive
materiality 0.75
Incyte Q2 total revenues up 29% to $911M; raises Jakafi guidance bottom end
INCYTE CORP
2022-Q2 EPS reported
$0.89
revenue$1,644,632,000
- Total revenues $911M (+29% YoY); product revenues $664M (+15% YoY).
- Jakafi net product revenues $598M (+13% YoY); FY guidance raised to $2.36-$2.40B.
- GAAP diluted EPS $0.72; Non-GAAP diluted EPS $1.01 (up from $0.80 YoY).
- Opzelura approved for vitiligo in July; ~48,000 units shipped in Q2 in atopic dermatitis launch.
- Itacitinib development in chronic GVHD halted; pivotal trial deemed unlikely to succeed.